Nautilus Biotechnology (NAUT) Cash from Investing Activities (2020 - 2026)

Nautilus Biotechnology has disclosed Cash from Investing Activities across 7 years of filings, most recently posting $14.2 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $14.2 million, down 27.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.9 million (down 52.77% YoY), and the FY2025 annual result was $35.2 million, down 46.83% from the prior year.
• Cash from Investing Activities came in at $14.2 million for Q1 2026 at Nautilus Biotechnology, up from $787000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $37.1 million in Q4 2024 to a low of -$64.1 million in Q4 2022.
• The 5-year median for Cash from Investing Activities is $13.1 million (2023), against an average of $2.7 million.
• Across the five-year window, Cash from Investing Activities slumped 1156.32% in 2022 and jumped 733.88% in 2024, its largest moves.
• Nautilus Biotechnology's Cash from Investing Activities stood at -$64.1 million in 2022, then soared by 35.9% to -$41.1 million in 2023, then soared by 190.37% to $37.1 million in 2024, then plunged by 97.88% to $787000.0 in 2025, then surged by 1708.51% to $14.2 million in 2026.
• The last three Cash from Investing Activities figures came in at $14.2 million (Q1 2026), $787000.0 (Q4 2025), and $452000.0 (Q3 2025), per Business Quant data.